US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Tue 21:00
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment Oct 20 (Reuters) - The US FDA said on Tuesday it had approved British drugmaker GSK's GSK.L hepatitis B drug Hibsago, offering patients with the liver infection a way to keep the virus under control after stopping treatment.
The drug, chemically known as bepirovirsen, is the first FDA-approved antisense oligonucleotide for chronic hepatitis B, according to the agency.
(Reporting by Padmanabhan Ananthan in Bengaluru and Bhanvi Satija in London; Editing by Diti Pujara)
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study